Download Files:
LY2510924
$100 – $1,550
Products Details
Product Description
– LY2510924 is a potent and selective CXCR4 antagonist that blocks SDF-1 binding to CXCR4 with an IC50 of 0.079 nM.
Web ID
– HY-12488
Storage Temperature
– -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)
Shipping
– Blue Ice
Applications
– Cancer-programmed cell death
Molecular Formula
– C62H88N14O10
References
– [1]Peng SB, et al. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models. Mol Cancer Ther. 2015 Feb;14(2):480-90.|[2]Cho BS, et al. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 2015 Jul 9;126(2):222-32.
CAS Number
– 1088715-84-7
Molecular Weight
– 1189.45
Compound Purity
– 99.73
SMILES
– O=C(NCC(N[C@H](CCC(N[C@H]1CC2=CC=CC=C2)=O)C(N[C@H](C(N)=O)CCCCNC(C)C)=O)=O)[C@@H](NC([C@@](NC([C@@H](NC([C@H](NC1=O)CC3=CC=C(O)C=C3)=O)CCCCNC(C)C)=O)([H])CCCNC(N)=N)=O)CC4=CC(C=CC=C5)=C5C=C4
Clinical Information
– Phase 2
Research Area
– Cancer; Endocrinology
Solubility
– DMSO : ≥ 125 mg/mL|H2O : ≥ 100 mg/mL
Target
– CXCR
Isoform
– CXCR4
Pathway
– GPCR/G Protein;Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
